Search
Boscalid
go.drugbank.com/drugs/DB12792ApprovedWithdrawnBoscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.
Categories: Heterocyclic Compounds, 1-RingRAG-17
go.drugbank.com/drugs/DB18503InvestigationalRAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).
Mannitol busulfan
go.drugbank.com/drugs/DB12097ApprovedWithdrawnMm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.
Asoprisnil
go.drugbank.com/drugs/DB06680InvestigationalAsoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.
Icotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersEtrolizumab
go.drugbank.com/drugs/DB12189Investigational[A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as
Asimadoline
go.drugbank.com/drugs/DB05104InvestigationalIt has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases. … Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.
Categories: Heterocyclic Compounds, 1-RingAutologous peripheral blood-derived CD34+ cells
go.drugbank.com/drugs/DB16367ApprovedInvestigational[L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage). … Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells.
VXA-CoV2-1
go.drugbank.com/drugs/DB16433InvestigationalThis oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell … responses to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins[L30498].
Lumiliximab
go.drugbank.com/drugs/DB06162InvestigationalIt is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. … Results published from the CLL clinical trial failed to meet primary endpoints.
Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER